Page 235 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
Laboratory of Hematology, Pitié-Salpêtrière Hospital, AP-HP, Paris Sorbonne University, Paris, France
Correspondence:
L. LHERMITTE - ludovic.lhermitte@aphp.fr
https://doi.org/10.3324/haematol.2024.285740
Received: April 22, 2024. Accepted: August 22, 2024. Early view: August 29, 2024.
©2025 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
MA declares consulting fees from Novartis. CL declares fee for congress from Novartis. JR and OH declare research funding from Novartis. All of the other authors have no conflicts of interest to disclose.
References
1. Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11):e646.
2. Wang SA, Orazi A, Gotlib J, et al. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023;98(8):1286-1306.
3. Arock M, Hoermann G, Sotlar K, et al. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. J Allergy Clin Immunol. 2022;149(6):1855-1865.
4. Yang Y, Létard S, Borge L, et al. Pediatric mastocytosis- associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT- phosphotransferase domain mutations. Blood. 2010;116(7):1114-1123.
5. Sánchez-Muñoz L, Morgado JM, Álvarez-Twose I, et al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol. 2016;172(1):56-63.
6. Escribano L, Díaz-Agustín B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001;25(7):563-570.
7. Álvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well- differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137(1):168-178.
8. Morgado JMT, Sánchez-Muñoz L, Teodósio CG, et al. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. Mod Pathol. 2012;25(4):516-521.
9. Lange M, yawrocki A, Nedoszytko B, et al. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate
Contributions
JR, SGL, OH, GD and LL are responsible for study conception and design. LL, CB, OB and VA are responsible for immunophenotypic analysis. DC is responsible for histopathology and immunohistochemistry. JR, SGL, DC, PD, OH, VA, GD and LL are responsible for data collection and analysis. JR, SGL, GD, OH and LL take principal responsibility for writing the manuscript. All authors gave their final approval of the manuscript for publication.
Acknowledgments
We thank the participating patients and their families, the members of the CEREMAST network, and the French Association for Research Initiatives on Mast Cells and Mastocytosis (AFIRMM). We thank Isabelle Hirsch for technical assistance.
Data-sharing statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
with systemic involvement in patients presenting with mastocytosis in the skin? Int Arch Allergy Immunol. 2014;165(2):104-110.
10. Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192-2199.
11. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541.
12. Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32(29):3264-3274.
13. Jawhar M, Schwaab J, Álvarez-Twose I, et al. MARS: mutation- adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37(31):2846-2856.
14. Schernthaner G-H, Jordan J-H, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98(13):3784-3792.
15. Naumann N, Rudelius M, Lübke J, et al. Poor applicability of currently available prognostic scoring systems for prediction of outcome in KIT D816V-negative advanced systemic mastocytosis. Cancers (Basel). 2024;16(3):593.
16. Sperr WR, Kundi M, Alvarez-Twose I, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6(12):e638-e649.
17. Polivka L, Madrange M, Bulai-Livideanu C, et al. Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes. JACI. 2024;153(1):349-353.e4.
Haematologica | 110 January 2025
227